PSYCHEDELIC DRUG DEVELOPMENT NEWS
Drug Developer Skips the Trip Entirely, Unveils Deuterium-Assisted Psychotherapy Candidate (Apr 1)
Initial reports describe the experience, though lacking psychedelics’ characteristic subjective effects, as “heavy” and “somewhat unstable”, but “noticeably patentable”.
Company Receives Notice of Allowance for U.S. Patent Covering Crystalline Polymorphs of Water (Apr 1)
The company announced the claims cover its lead candidate, Polymorph Eau.
Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales expectations for its life science
Eli Lilly is on a hot streak. It’s about to find out whether its diabetes drug can also be marketed for weight management. Its Alzheimer’s
This year’s headlines on COVID-19 featured new research on COVID-related mortality, post-acute sequelae of infection, vaccine safety, and potential therapeutics. COVID Deaths Are Down, but…